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Abstract
Background: American visceral leishmaniasis is caused by the intracellular parasite Leishmania (L.) infantum chagasi,
and transmitted by the sand fly Lutzomyia longipalpis. Since treatment is based on classical chemotherapeutics
with significant side effects, the search for new drugs remains the greatest global challenge. Thus, this in vitro study
aimed to evaluate the leishmanicidal effect of Crotalus durissus terrificus venom fractions on promastigote and
amastigote forms of Leishmania (L.) infantum chagasi.
Methods: Phospholipase A2 (PLA2) and a pool of peptide fraction (<3 kDa) were purified from Crotalus venom.
Furthermore, promastigotes and peritoneal macrophages of mice infected by amastigotes were exposed to serial
dilutions of the PLA2 and peptides at intervals varying between 1.5625 μg/mL and 200 μg/mL. Both showed activity
against promastigotes that varied according to the tested concentration and the time of incubation (24, 48 and
72 h).
Results: MTT assay for promastigotes showed IC50 of 52.07 μg/mL for PLA2 and 16.98 μg/mL for the peptide
fraction of the venom. The cytotoxicity assessment in peritoneal macrophages showed IC50 of 98 μg/mL and
16.98 μg/mL for PLA2 and peptide by MTT assay, respectively. In peritoneal macrophages infected by Leishmania
(L.) infantum chagasi amastigotes, the PLA2 stimulated growth of parasites, and at higher doses reduced growth
by 23 %. The peptide fraction prevented 43 % of the intracellular parasite growth at a dose of 16.98 μg/mL,
demonstrating the toxicity of this dose to macrophages. Both fractions stimulated H2O2 production by
macrophages but only PLA2 was able to stimulate NO production.
Conclusion: We have demonstrated the in vitro leishmanicidal activity of the PLA2 and peptide fraction of Crotalus
venom. The results encourage further studies to describe the metabolic pathways involved in cell death, as well as
the prospecting of molecules with antiparasitic activity present in the peptide fraction of Crotalus durissus terrificus
venom.
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Background
The epidemiological relevance of American visceral
leishmaniasis, caused by the parasite Leishmania (L.)
infantum chagasi, as a neglected disease has increased
significantly in Latin America and especially in Brazil,
where 90 % of the cases occur [1, 2]. Transmitted by the
bite of Lutzomyia longipalpis, infected with promastigote
forms, dogs are considered the principal reservoir for
humans [1, 3–5].
Its treatment is carried out via chemotherapeutics
such as amphotericin B and pentamidine as well as
meglumine antimonate and sodium stibogluconate, all of
which present high indices of serious side effects [6–8].
The infection triggers a cluster of clinical manifestations
that can lead to death, if the patient is not treated. The
toxicity of drugs, the difficulties of administration and
the duration of treatment, allied with their low efficacy
for humans and practical inefficacy for other animals,
has stimulated the research of new natural leishmanici-
dal compounds, such as those derived from animal
venoms [9].
Snake venoms are composed of a complex mixture of
distinct proteins and present different pharmacological
activities that can generate different active molecules
[10]. The venom of Bothrops mojeeni can inhibit the
growth of Leishmania spp. due to the hydrogen peroxide
generated by the activity of the enzyme L-amino acid
oxidase [11]. Venoms from Cerastes, Vipera, and Naja
also exert an inhibitory effect on growth of Leishmania
infantum donovani [12]. The venom of Crotalus durissus
cascavella has three main fractions that present antil-
eishmanial activity. The South American rattlesnake
Crotalus durissus terrificus (Cdt) possesses several bio-
logically active proteins in its venom, such as giroxin,
crotamine, convulxin, crotoxin and peptides.
Crotoxin, the major toxic component of Cdt venom, is
constituted by two subunits, an acid one without enzym-
atic action called crotapotin, and a basic one that presents
the function of phospholipase A2 (PLA2), which possesses
neurotoxic and myotoxic action [13, 14]. Evaluations of
the in vitro action of PLA2 from snakes of the genus
Bothrops against promastigote forms of Leishmania sp.
have obtained encouraging results against these parasites
[15–17]. Another important component of Cdt venom is
its peptide fraction, which is composed of low-molecular-
weight molecules. Despite previous descriptions of this
peptide fraction having presented anesthetic action and
natriuretic peptides, neither of these two aspects has been
evaluated against Leishmania.
Considering that snake venoms constitute a great
source of bioactive protein substances that can act on
diverse physiological systems, the present work aimed to
evaluate the action of PLA2 and of the peptide fraction
from Crotalus durissus terrificus snake venom against
Leishmania (L.) infantum chagasi, in in vitro infection of
murine macrophages and in a culture of promastigotes.
Methods
Crotalus durissus terrificus (Cdt) venom was kindly
provided by the Center for the Study of Venoms and
Venomous Animals, UNESP, Botucatu, Brazil. The en-
tire procedure followed the ethical principles for ani-
mal experimentation adopted by the Brazilian College
of Animal Experimentation (COBEA), and was ap-
proved by the Ethics Committee for Animal Experi-
mentation at the Botucatu Medical School, UNESP,
CEEA 890-2011.
Protein quantification was determined by the Bradford
method [18] using bovine serum albumin (BSA) as the
molecular standard (Sigma, USA). Electrophoresis was
carried out under denatured conditions on 13 % (m/v)
polyacrylamide, in order to evaluate the purity of the
samples and the molecular masses of the proteins
isolated [19].
The purification of PLA2 was performed utilizing the
Äkta Explorer 100 (GE HealthCare®) by three chromato-
graphic steps. In the first two, the chromatographic
strategy adopted was molecular exclusion, utilizing the
column Hiprep 26/60/Sephacryl S-100 HR (2.6 × 60 cm,
GE HealthCare®). The chromatographic reading was
done with a flow of 1 mL/min under absorbance of
280 nm. One gram of lyophilized Cdt venom was eluted
in 50 mM of ammonium formate and 150 mM of NaCl,
pH 3.5. The fraction eluted between the volumes 40 and
60 mL was collected and lyophilized, being re-
chromatographed under the same described conditions.
Next, the fraction eluted between the volumes 42 and
52 mL was collected and lyophilized again. The third
step, namely purification, employed an ion-exchange
strategy by means of the Hitrap DEAE column (0.7 ×
2.5 cm, 1 mL, GE HealthCare®) previously equilibrated
in a 6 M buffer of urea and 50 mM of Tris, pH 7.3. A
100 μL solution with a concentration of 2.7 μg/mL of
purified protein fraction diluted in equilibrium buffer
was injected at a flow rate of 0.5 mL/min and absorb-
ance of 280 nm, under a gradient from 0 to 100 % of
buffer of 6 M urea, 50 mM Tris and 1 M NaCl. After
27 min, the fraction of interest was collected [20].
PLA2 was identified by phospholipase activity [16]
and by sequencing of amino acids from their N-
terminal portion by the Edman Degradation Chemis-
try technique [21] using automated equipment, model
PPSQ-21 (Shimadzu®), following the manufacturer’s
standard instructions. SDS-PAGE was performed under
reducing or non-reducing conditions using a 13.5 % poly-
acrylamide gel [16]. These procedures were employed to
evaluate whether the protein isolated was of interest for
the present study.
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To obtain the pool of peptide fraction (<3 kDa), 300 mg
of lyophilized Cdt venom was diluted in 2 mL of 0.1 %
TFA (v/v) and homogenized. The supernatant was placed
in a spin concentrator, model Viva Spin 2-3000 MW (GE
HealthCare®) and centrifuged at 3000 rpm for 30 min. This
process was repeated three times until the entire peptide
fraction had passed through the concentrator [22].
The L. (L.) infantum chagasi promastigotes (MHOM/
BR/1972/LD) were maintained in agar-blood biphasic
medium, Novy-MacNeal-Nicolle (NNN), associated with
liver infusion tryptose (LIT) medium supplemented with
10 % (v/v) bovine fetal serum (BFS), 10 mg/mL of genta-
micin in a humid incubator (Biologic Oxygen Demand
TE-381) at 25 °C, containing 5 % CO2 [23]. Subculturing
was carried out every 15 days. The macrophages were
obtained from the peritoneal cavity of BALB/c mice by
washing with 3 mL of culture medium RPMI-1640
(Roswell Park Memorial Institute) supplemented with
10 % (v/v) BFS and were maintained at 37 °C in an atmos-
phere of 5 % CO2 [24].
To determine the 50 % inhibitory concentration (IC50)
against promastigotes of L. (L.) infantum chagasi in the
latest logarithmic phase of growth, the cultures were
washed three times in phosphate buffer (PBS) and their
concentration was adjusted to 106/mL, starting from the
counting performed in a Neubauer chamber. Subse-
quently, culture aliquots containing 5 × 105 parasites
were applied in 96-well plates with LIT medium supple-
mented with 10 % BFS. The PLA2 and the peptide frac-
tion of the Cdt venom were dissolved in PBS, and
serially diluted starting from an initial concentration of
200 μg/mL, with dilution factor 2, that were next added
individually to cultures. Amphotericin B was employed
as positive control (0.890 μg/mL) and PBS as negative
control.
The in vitro susceptibility of Leishmania (L.) infantum
chagasi promastigotes treated with PLA2 and the peptide
fraction of Cdt venom was determined by the colorimet-
ric method and by studying the mitochondrial oxidative
activity using MTT tetrazolium salt at a concentration
of 5 mg/mL, diluted in PBS, sterilized in a 0.22 μm meth-
ylcellulose membrane (Millipore®). Then, 20 μ/L per well
was added, which was incubated for 4 h at 24 °C. The
isolated incubated promastigotes were utilized as a
viability control. The reenzymatic action was analyzed,
whereas the precipitate was solubilized by the
addition of 80 mL of SDS 10 % (m/v) dissolved in
Milli-Q water; the optical density (OD) was deter-
mined by utilizing a plate reader (Multiskan MS,
Uniscience®) at 550 nm. The definition of 100 % via-
bility was based on the OD of the control [24].
To determine the 50 % inhibitory concentration (IC50)
against intracellular amastigotes of Leishmania (L.)
infantum chagasi, peritoneal macrophages were obtained
from BALB/c mice, and the cellular concentration was
adjusted to 8 × 105 cells/mL. Next, the cell suspension
was incubated on 16-well Nunc® microculture plates,
(System Deslize™ Lab-Tek Chamber, USA) coupled with
a histological slide, at the proportion of 4 × 105 cells/well
and maintained at 37 °C in an atmosphere of 5 % CO2
for a period of 24 h so that the macrophages would
adhere to the plate. The supernatant was removed and
added to RPMI-1640 medium supplemented with 10 %
BFS. After this period, PLA2 and the peptide fraction of
the Cdt venom were dissolved in PBS, and serially
diluted starting from an initial concentration of 100 μg/
mL, with dilution factor 2, that were next added indi-
vidually to cultures. Untreated infected macrophages
were used as control. The assays were performed in trip-
licate, and evaluated after 24, 48 and 72 h by optical
microscopy. The slides were fixed with methanol and
stained with Giemsa. IC50 was determined by counting
500 macrophages per well and evaluating the number of
infected macrophages. Amphotericin B was employed as
positive control (IC50 0.890 μg/mL) and PBS as negative
control [25].
To evaluate the cytotoxicity in mammalian cells, the
peritoneal macrophages (4 × 105 cells/well) were incu-
bated with 200 μg/mL of PLA2 and with 100 μg/mL of
peptide fraction from Cdt and serially diluted at 37 °C in
an atmosphere of 5 % CO2 for a period of 24 h and 48 h
[26, 27]. Amphotericin B (0.890 μg/mL) was employed
as positive control. Mammalian cellular viability was de-
termined by the MTT assay using the microplate reader
MS Multi-skan (Uniscience®) at 550 nm.
For the determination of nitric oxide (NO) production,
the infected macrophages were incubated in microtubes
containing different concentrations of PLA2 and of the
peptide fraction (200 μg/mL, 100 μg/mL, 50 μg/mL,
25 μg/mL, 12.5 μg/mL, 6.25 μg/mL, 3.125 μg/mL,
1.5625 μg/mL) for 24, 48 and 72 h. After each incuba-
tion, the recollected supernatant was applied into 96-
well microplates for measurement of nitrite (NO2) and
nitrate (NO3). The nitrite concentration was verified by
the reaction of Griess. The results were obtained by
means of MS Multiskan microplates (Uniscience®) at
540 nm, in comparison to a zero standard consisting of
Griess reagent. All the measurements were performed in
triplicate and the results were expressed in micromoles
of NO/2 × 105 cells, starting from the standard curve
established by known concentrations of molarities from
0.39 to 200 μM NO2
- . The control was constituted by
cells treated with lipopolysaccharide (LPS), and by un-
treated cells [28, 29].
The production of H2O2 was evaluated by incubation
of peritoneal macrophages with different concentrations
of PLA2 and of the peptide fraction (200 μg/mL, 100 μg/
mL, 50 μg/mL, 25 μg/mL, 12.5 μg/mL, 6.25 μg/mL,
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3.125 μg/mL, 1.5625 μg/mL), for 24, 48 and 72 h. Added
to the macrophages after each incubation period was
100 μL of a buffer containing 140 mM NaCl, 10 mM
phosphate, pH 7, 5.5 mM Dextrose, 0.56 mM phenol red
and 0.01 mg/mL peroxidase Type II (Sigma Chemical Co,
USA) in each well. The plates were incubated at 37 °C, in
an atmosphere of 5 % CO2 for 4 h, and the reaction was
stopped for the addition of 0.01 mL of 1 N NaOH. The
absorbance was determined in an automatic microplate
reader (MD 5000®, Dynatech Laboratories Inc., USA) with
a 620 nm filter in relation to a “zero standard” consisting
of phenol red and 1 N NaOH. All measurements
were performed in triplicate whereas H2O2 produc-
tion was expressed in nanomoles/2 × 105 cells, accord-
ing to the standard curve established for each test.
Under the experimental conditions, the curve was
generated with the H2O2 concentrations of 0.5; 1.0;
2.0; 4.0 and 8.0 mM. The control was composed of
cells treated with phorbol myresteate acetate (PMA)
and of untreated cells [30].
Data (mean ± SD, MPa) were analyzed by one-way
ANOVA and Tukey test (p < 0.05). Nonparametric data
were expressed as median and were analyzed using the
Mann-Whitney test (p < 0.05). All analysis was per-
formed with GraphPad PRISM® Version 1.5 software
(GraphPad Software Inc., USA).
Results
Purification of PLA2 and of peptide fraction from Cdt
venom
Figure 1 – a shows the chromatographic profile resulting
from the molecular exclusion of venom from Cdt. The
eluted peaks between 40 and 60 mL (peak 3) were re-
chromatographed by the same technique (Fig. 1 – b). Then,
the peaks eluted between 43 and 53 mL (peak 3.1) were
submitted to ion-exchange chromatography. Figure 1 – c
shows the elution of two distinct peaks. Peak 3.1.2
was identified as PLA2 and confirmed by SDS-PAGE
(Fig. 1 – d), phospholipase activity (Fig. 2) and Edman
sequencing (data not shown).
Leishmanicidal activity
Figure 3 (a and b) displays leishmanicidal activities of
PLA2 toxin and of the Cdt peptide fraction, respectively.
The MTT colorimetric method in microplates revealed
that the IC50 levels were 52.07 μg/mL for PLA2 and
16.98 μg/mL for the peptide fraction. Amphotericin B
(positive control) showed IC50 0.089 μg/mL.
Cytotoxic activity in macrophages
Figure 4 (a and b) shows the cytotoxicity of PLA2 and
the peptide fraction of Cdt by utilizing peritoneal macro-
phages of BALB/c mice, as evaluated via MTT colorim-
etry. The IC50 levels were, respectively, 52.07 μg/mL for
PLA2, and 16.98 μg/mL for the peptide fraction.
Determination of production of Nitric Oxide (NO) and
Hydrogen Peroxide (H2O2)
Figure 5 (a, b and c) displays the NO production of
supernatant from murine macrophages infected by L.
(L) chagasi treated with PLA2, measured at three dif-
ferent incubation moments (24, 48, and 72 h). At 24 h
(Fig. 4 – a), NO production by the lipopolysaccharide-
treated control (LPS) was greater than that of the control
constituted by untreated macrophages (MO). In relation
to the production of NO between the treatments with
PLA2 and the controls, the treatments T1, T3, T5, T6 and
T8 did not differ from the MO control. As to the LPS
control, these treatments produced less NO. The treat-
ment T4 differed from the other treatments T1, T3, T5,
T6 and T8 and the MO control, but did not present a
Fig. 1 a Chromatographic profile of Crotalus durissus terrificus venom by molecular exclusion technique. The peaks correspond to convulxin [1], giroxin
[2], crotoxin [3] and crotamine [4]. b Chromatographic profile of crotoxin fraction of Crotalus durissus terrificus venom by molecular exclusion step. c
Chromatographic profile of crotoxin fraction of Crotalus durissus venom by ion exchange step, evidencing crotapotin [1] and PLA2 [2]. d SDS-PAGE of
weight marker (WM), whole venom (WV) and PLA2
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difference in relation to the LPS control. The treatment
T7 differed significantly only from the MO control.
After 48 h of incubation (Fig. 5 – b), treatment T2
presented higher production than the untreated group,
but did not differ from the LPS control. Treatment T7
presented greater production than the untreated control,
but showed no difference in relation to the LPS-treated
control. The treatments T5 and T6 produced less NO
than the LPS-treated group. At 72 h (Fig. 5 – c), a
tendency toward increasing NO production was found
only in the PLA2-treated groups although there was no
significant difference in relation to the controls. The
peptide fraction was unable to stimulate the production
of NO by macrophages.
Figure 6 (a, b and c) shows the production of H2O2 in
the supernatant of macrophages treated with PLA2 at
24, 48 and 72 h. At 24 h of incubation (Fig. 5 – a), a dif-
ference in relation to the two controls was observed only
in treatment T1. At 48 and 72 h (Fig. 6 – b and c), an
increase of H2O2 production was found, most promin-
ently after 72 h, when all the treated groups differed
(p < 0.05) from the controls. There was no difference
among the treatments.
Figure 7 (a, b and c) displays the H2O2 production in
the supernatant of macrophages treated with Cdt pep-
tide fraction at 24, 48, and 72 h. At 24 h of incubation
(Fig. 7 – a), the controls did not differ from the treat-
ments (p < 0.05). At 48 h of incubation (Fig. 7 – b), a sig-
nificantly greater production of H2O2 was observed in
treatments T3, T6 and T7 (p < 0.05) in relation to the con-
trols MO and PMA. After 72 h of incubation, in all the
treatments, the H2O2 production was higher (p < 0.05)
than those of PMA and the MO controls.
Fig. 2 Phospholipase activity of peak 3.1.2 purified from Crotalus
durissus terrificus venom
Fig. 3 a Dose-response curve of MTT assay for leishimanicidal activity
of PLA2 and (b) of peptide fraction from Crotalus durissus terrificus
venom in promastigotes of Leishmania (L.) infantum chagasi
Fig. 4 a Dose-response curve of MTT assay for cytotoxicity in murine
macrophages of PLA2 and of (b) peptide fraction from Crotalus durissus
terrificus venom
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Discussion
An antiparasitic effect of snake venom has been amply
described with the aim of discovering target molecules.
The ultrastructural alterations caused by these venoms
in parasites involve mitochondrial edema and kinetoplast
dysregulation or intense cytoplasmic vacuolization and
enlargement of the flagellar pocket [17, 31]. The venoms
can affect the respiratory chain through ATP leakage in
promastigotes and, therefore, these organelles would be
the first to suffer from the treatment [11, 31].
In our present work, we have noted that the PLA2
isolated and purified from the venom of Crotalus
durissus terrificus (Cdt) was able to inhibit the prolif-
eration of Leishmania chagasi promastigotes at a rate
from 50 % to 83 % at doses from 50 to 200 μg/mL,
respectively. It was also observed that this inhibition
rate was dose-dependent.
The action of PLA2 from venom of snakes of the
genus Bothrops in the inhibition of Leishmania promas-
tigote growth was described against Leishmania major,
L. (L.) amazonensis, L. (V.) braziliensis, and L. chagasi
[15–17]. The results found for PLA2 from Cdt corrobor-
ate these observations, despite small differences in the
composition of PLA2 and in the susceptibility of the
parasites. The PLA2 of Cdt is an enzymatically active
Asp-49 whose action is associated with its catalytic site
while it interacts hydrophobically with the plasma mem-
brane penetrating into the lipid bilayer, causing an elec-
trostatic perturbation and thereby rupturing the
membrane [18, 27, 32, 33]. This direct action may have
caused the inhibition of promastigote growth observed
in our study.
In vivo studies have shown that promastigotes of
Leishmania amazonensis treated with PLA2 purified
from Crotalus durissus colilineatus venom augment the
size of lesions in BALB/c mice. A prior study indicated
that PLA2 appears to be a factor in the progression of
cutaneous leishmaniasis, since macrophages treated with
PLA2 presented elevated levels of prostaglandin E2
(PGE2) (an inflammatory lipid mediator) and inhibited
levels of IL-2, a cytokine associated with Th-1 response
[34]. The results of the present study corroborate these
authors since weaker dilutions of the PLA2 utilized to
treat the peritoneal macrophages infected by L. (L)
infantun chagasi amastigotes induced the proliferation
of parasites inside the macrophages, while at doses
higher than 50 μg/mL they were able to diminish the in-
fection by up to 27.3 %.
Fig. 5 Means ± standard deviation of the mean (p < 0.05) of NO production in supernatant of murine macrophages infected by L. (L.) chagasi
treated with PLA2 at three different incubation moments: (a) 24 h, (b) 48 h, and (c) 72 h. The control was done without treatment (MO) and with
lipopolysaccharide (LPS). The PLA2 doses utilized in the treatment (T) were T1 = 100 μg/mL; T2 = 50 μg/mL; T3 = 25 μg/mL; T4 = 12.5 μg/mL;
Tr5 = 6.25 μg/mL; T6 = 3.125 μg/mL; T7 = 1.5625 μg/mL; T8 = 0.78125 μg/mL
Fig. 6 Means ± standard deviation of the mean (p < 0.05) of H2O2 production by peritoneal macrophages of murine macrophages infected by L. (L.)
chagasi treated with PLA2 at three different incubation moments: (a) 24 h, (b) 48 h, and (c) 72 h. The control was performed without treatment (MO)
and with stimulation by PMA. The PLA2 doses utilized in the treatment (T) were T1 = 100 μg/mL; T2 = 50 μg/mL; T3 = 25 μg/mL; T4 = 12.5 μg/mL;
T5 = 6.25 μg/mL; T6 = 3.125 μg/mL; T7 = 1.5625 μg/mL; T8 = 0.78125 μg/mL
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The low-molecular weight compounds found in snake
venoms have aroused the interest of the pharmaceutical
industry due to their great variety of pharmacological
effects. The peptides that have already been isolated
from snake venoms include: type-C natriuretic peptides,
bradykinin-potentiating peptides (BPPs), sarafotoxins,
waglerins and peptides that present inhibitory activity
against metalloproteinases, and antimicrobial peptides
[25, 35].
The antimicrobial peptides, which represent an ex-
tremely diverse group, participate primarily in the innate
immune system by acting as an initial barrier of immune
defense in many organisms, including plants, insects,
bacteria and vertebrates [26, 36, 37]. The peptide Pep5Bj,
from the venom of Bothrops jararaca, presents a high
level of inhibitory activity against the growth of the fungi
Fusarium oxysporum and Colletotrichum lindemuthia-
num and the yeasts Candida albicans and Saccharomy-
ces cerevisiae [38].
The peptide fraction of Cdt venom presented an IC50
of 16.98 μg/mL for antileishmanial activity against the
promastigotes, equivalent to the cytotoxic activity IC50
of 16.98 μg/mL, and is able to inhibit the growth of not
only promastigotes, but also 43 % of amastigotes at the
same dose.
An important factor in leishmaniases is the action of
macrophages, since they are the main host cells of the
parasite, and also play an important role in the control of
parasites, by means of producing cytokines and metabolic
oxygen compounds such as nitric oxide (NO) [37, 39].
The action mechanism of NO, as well as its specific
targets within the metabolic pathways in Leishmania sp.,
were previously described as was their susceptibility to
NO production by the host cell [36, 37]. In our study,
the quantity of NO produced during the infection was
measured at 24, 48, and 72 h, showing different results
among these moments. At 24 h, the controls differed
from treatment T7 (1.5625 μg/mL). After 48 h of
treatment, there was a difference between the control
groups, as well as between some of the treated groups.
Yet at 72 h, greater NO production was shown, even in
the controls.
The production of NO, one of the main microbicidal
agents from murine macrophages, can be stimulated by
the action of PLA2 from Cdt venom [40]. However, some
species of Leishmania, such as L. Amazonensis and L.
chagasi, are able to inhibit NO production [41]. In this
manner, we may infer that in the first 24 h of treatment,
the parasites had supported the cellular defenses through
some mechanism of escape. But after 72 h the defenses
produced by the macrophages would become sufficient to
suppress the modulation of the parasite in the macro-
phage defenses. In this sense, the action of PLA2 impeded
the parasite from maintaining its escape mechanism, a fact
also observed in a prior study that measured the produc-
tion of TNF-α, NO, and IL-10 in treatment with PLA2
from B. pauloensis in experimental infection of murine
macrophages with L. amazonesis [17].
It is important to emphasize that in relation to NO
production by a pool of peptides, there was no difference
between the treatments and the controls, in any of the
readings.
H2O2 is an antiparasitic compound that is produced
by defense cells such as macrophages, when challenged
by such intracellular parasites as Leishmania sp. A dif-
ference in H2O2 production was observed in our study
only at 48 h of treatment.
Previous studies demonstrate the resistance of Leish-
mania spp. to H2O2, where it could be noted that the
parasites produce catalase and superoxide dismutase, en-
zymes that confer an efficient escape mechanism from
the action of H2O2 [15, 17, 35]. This resistance of the
parasite to H2O2 production may account for the low
production of this metabolite in the first 24 h, after
which the activity of the peptide fraction perturbed
the metabolism of the parasites, by which the parasite
Fig. 7 Means ± standard deviation of the mean (p < 0.05) of H2O2 production by peritoneal macrophages of murine macrophages infected by L.
(L.n chagasi treated with Cdt peptide fraction, at three different incubation moments: (a) 24 h, (b) 48 h, and (c) 72 h. The control was done
without treatment (MO) and with stimulation by PMA. The PLA2 doses utilized in the treatment (T) were T1 = 100 μg/mL; T2 = 50 μg/mL;
T3 = 25 μg/mL; T4 = 12.5 μg/mL; T5 = 6.25 μg/mL; T6 = 3.125 μg/mL; T7 = 1.5625 μg/mL; T8 = 0.78125 μg/mL
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ceases or diminishes the production of enzymes that
degrade H2O2.
Conclusion
Due to the high toxicity presented by drugs utilized for
the treatment of leishmaniases and their important side
effects, it has become necessary to seek new molecules
with therapeutic potential against these diseases. In this
context, the present work has demonstrated in vitro
leishmanicidal activity of the PLA2 and peptide fraction
of Crotalus dutissus terrificus venom. New studies must
be performed to describe the metabolic pathways in-
volved in the process of cellular death. Furthermore, the
prospecting of molecules whose peptide fraction pre-
sents antiparasitic activity, as well as the immunomodu-
lation of these new molecules, must be investigated.
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